@prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "indications and usage prednisone tablets are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in collagen diseases during an exacerbation or as maintenance therapy in selected cases of dermatologic diseases pemphigus allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as respiratory diseases symptomatic sarcoidosis hematologic disorders idiopathic thrombocytopenic purpura in adults neoplastic diseases for palliative management of edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "DSNXiRHQAV3QW5w0L5ScJppgwJ4nluer4DMoeCICFAFSLguWlIpxPTx5sV2svKldjvrgqzrtfgjWmBfxVh586If5VQLX/xEveQuPacWmCVW37XMSSWXi0/I1MpiRjYr0j+9ZkX+/HigjoexfsGkmtzw3MQ8UhyU4xD/g8mVnBdE="; npx:hasSignatureTarget this: . this: dct:created "2021-06-13T12:54:01.486+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }